Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $1.6 billion.

  • UNITED THERAPEUTICS's Beginning Cash Balance rose 17.51% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 40.28%. This contributed to the annual value of $1.2 billion for FY2024, which is 25.65% up from last year.
  • UNITED THERAPEUTICS's Beginning Cash Balance amounted to $1.6 billion in Q3 2025, which was down 16.15% from $1.9 billion recorded in Q2 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's Beginning Cash Balance peaked at $1.9 billion during Q2 2025, and registered a low of $738.7 million during Q1 2021.
  • Moreover, its 3-year median value for Beginning Cash Balance was $1.3 billion (2024), whereas its average is $1.4 billion.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Beginning Cash Balance declined by 15.60% in 2022, and later skyrocketed by 51.81% in 2025.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Beginning Cash Balance stood at $908.5 million in 2021, then rose by 6.42% to $966.8 million in 2022, then climbed by 14.57% to $1.1 billion in 2023, then soared by 40.28% to $1.6 billion in 2024, then grew by 17.51% to $1.6 billion in 2025.
  • Its Beginning Cash Balance was $1.6 billion in Q3 2025, compared to $1.9 billion in Q2 2025 and $1.7 billion in Q1 2025.